42nd Annual Canaccord Genuity Global Growth Conference

Aug 11, 2022

Thursday, August 11 at 8:00am ET VIEW PRESENTATION or VIEW WEBCAST News 2020 2021 2022 Events Past...

Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

Aug 4, 2022

CAMBRIDGE, Mass. August 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming...

Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)

Jun 28, 2022

– Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 – AD109 Phase 3 development program expected to be initiated in late 2022  CAMBRIDGE, Mass. June 28, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...

Apnimed Adds Ruoxi Hu, PhD, from Morningside Technology Advisory to its Board of Directors

Jun 16, 2022

CAMBRIDGE, Mass. June 16, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that Ruoxi (Rosy) Hu, Ph.D., from Morningside...

Jefferies 2022 Investor Conference & Summit

Jun 10, 2022

Friday, June 10 at 9:00am ET VIEW PRESENTATION News 2020 2021 2022 Events Past...